TransCode Therapeutics Initiates Strategic Review of Oncology Assets
TransCode Therapeutics has engaged Tungsten Advisors to evaluate strategic alternatives for its oncology portfolio, specifically focusing on the clinical-stage candidate TTX-MC138.
Boston-based biotech firm TransCode Therapeutics has launched a formal process to evaluate strategic alternatives for its oncology portfolio. The company has retained Tungsten Advisors to lead the search for potential transactions, including licensing agreements, joint development partnerships, or other strategic arrangements aimed at maximizing shareholder value.
The review centers on the company’s lead program, TTX-MC138, which is currently undergoing Phase 2a clinical trials. The therapy is designed to treat patients with colorectal cancer who remain ctDNA-positive following curative-intent surgery or treatment, a segment representing a significant area of unmet medical need.
By engaging external advisors, TransCode aims to secure the resources necessary to continue its clinical development pipeline. The company has not provided a specific timeline for the conclusion of the strategic review.